GLPGF News and Press, Galapagos Genomics Ord From 02/23/24

2024-02-23 10:23:03 ET Galapagos NV (GLPG) Q4 2023 Earnings Conference Call February 23, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating O...

Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €...

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translatio...

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jysel...

Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the San Francisco area Agreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the Boston are...

Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and development with BridGene’s innovative discover...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

2024-01-02 02:37:43 ET More on Galapagos: Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma For further details see: Galapagos to transfe...

Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfa...

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T...